Skip to content
Biodatica
Start free

Keymed Biosciences Co.Ltd

Beijing

Oncologygene editingPhase III
Compare Sign in to watch

What changed

NIH R01 · $0.7M · Trans-omics Analysis of African American Deceased Donor Kidneys for Transplant Outcomes.

Jun 2025Grant renewalJun 30, 2025Source filing (opens the source filing in a new tab)

Momentum

51no change

Momentum 51 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

329 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $565k · non-dilutive

    Jun 10, 2025

    UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MA, LI · NCI · award ends May 31, 2030 · Study of a new driver and therapeutic vulnerability of bone metastasis

    NIH RePORTER · NIH RePORTER 11201506 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    May 1, 2025

    Atopic Dermatitis · NOT_YET_RECRUITING · sponsor: Keymed Biosciences Co.Ltd · Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

    ClinicalTrials.gov · NCT06956196 (opens the source filing in a new tab)

  3. Grant

    R01 · $662k · non-dilutive

    Sep 1, 2024

    WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FREEDMAN, BARRY IRA · NIDDK · award ends Jun 30, 2028 · Trans-omics Analysis of African American Deceased Donor Kidneys for Transplant Outcomes.

    NIH RePORTER · NIH RePORTER 11176080 (opens the source filing in a new tab)

  4. Grant

    U2C · $97k · non-dilutive

    Sep 1, 2024

    UNIVERSITY OF WASHINGTON · PI FREEDMAN, BENJAMIN SOLOMON · NIDDK · award ends May 31, 2029 · Professional Development Core

    NIH RePORTER · NIH RePORTER 11168857 (opens the source filing in a new tab)

  5. Grant

    R00 · $244k · non-dilutive

    Mar 1, 2020

    BETH ISRAEL DEACONESS MEDICAL CENTER · PI FREEDMAN, BENJAMIN ROSS · NIA · award ends May 31, 2027 · Multifunctional tough adhesive hydrogels to recruit, expand, and deliver tendoncells during aging and injury

    NIH RePORTER · NIH RePORTER 11099871 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources